glp 1 receptor agonists names A schematic overview of GLP-1 agonists: classification, drug Trends in the Development of

In conclusion, GLP-1RA is a promising candidate drug therapy for pediatric MASLD, and patients may benefit from metabolic improvement even if the liver disease ameliorating effects are not yet clear

Challenges include gastrointestinal side effects, nutritional deficiencies due to calorie reduction, muscle and bone loss, low long-term adherence with subsequent weight regain, and high costs, resulting in low cost-effectiveness

Given the strong association between MASLD and cardiovascular pathology, that represents the primary cause of death in this population, the cardioprotective benefits of GLP-1 RAs provide important additional clinical value beyond hepatic benefits

RC: These medications are not just about the number on the scale

tirzepatide is under patent protection until at least 2036

Consensus statement by the American Association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm 2016 executive summary